PLASMACYTOMA
Clinical trials for PLASMACYTOMA explained in plain language.
Never miss a new study
Get alerted when new PLASMACYTOMA trials appear
Sign up with your email to follow new studies for PLASMACYTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Dual-Target CAR-T therapy takes on High-Risk myeloma
Disease control Recruiting nowThis early-phase trial tests a new type of CAR-T cell therapy that targets two cancer markers (BCMA and GPRC5D) in people with high-risk multiple myeloma or plasmacytoma. The goal is to see if it is safe and can control the disease as a first treatment. About 20 participants will…
Matched conditions: PLASMACYTOMA
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental Dual-Target CAR-T therapy takes aim at Hard-to-Treat plasma cell cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of gene therapy called CAR 70-BCMA dual-target CAR-T for people with relapsed or refractory plasma cell neoplasms, including multiple myeloma. The therapy involves taking a patient's own immune cells, re-engineering them to recognize a…
Matched conditions: PLASMACYTOMA
Phase: EARLY_PHASE1 • Sponsor: The General Hospital of Western Theater Command • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC